Contact information
Colleges
Michael Desborough
BMedSci(Hons), MBChB, MRCP, FRCPath, DPhil
Locum Consultant Haematologist & Honorary Senior Lecturer
The main focus of my research is assessing whether desmopressin could be used for treatment of thrombocytopenia or platelet dysfunction.
Platelets are a key part of clot formation. Patients with too few platelets, or platelets which are dysfunctional, are vulnerable to bleeding. One way to treat these patients is by transfusing platelets from a blood donor but this approach is often not effective. I am aiming to determine if desmopressin (a drug which increases platelet adhesion by stimulating release of Von Willebrand Factor) could be an effective adjuvant, or alternative treatment.
I am using a combination of methods to assess the value of desmopressin in this setting including meta-analysis of randomised controlled trials; laboratory assessment of thrombus formation under flow; and observational trials. I am leading two randomised placebo-controlled feasibility trials: desmopressin for prevention of bleeding in thrombocytopenia (DRIVE) and desmopressin for treatment of stroke due to haemorrhage (DASH).
Key publications
-
Desmopressin use for minimising perioperative blood transfusion.
Journal article
Desborough MJ. et al, (2017), Cochrane Database Syst Rev, 7
-
Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials.
Journal article
Desborough MJR. et al, (2017), J Thromb Haemost, 15, 263 - 272
-
Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials.
Journal article
Odutayo A. et al, (2017), Lancet Gastroenterol Hepatol, 2, 354 - 360
-
Effect of restrictive versus liberal red cell transfusion strategies on haemostasis: systematic review and meta-analysis.
Journal article
Desborough MJR. et al, (2017), Thromb Haemost, 117, 889 - 898
-
Alternatives to allogeneic platelet transfusion.
Journal article
Desborough MJR. et al, (2016), Br J Haematol, 175, 381 - 392
Recent publications
-
A HaemSTAR is born; a trainee-led, UK-wide research network in haematology.
Journal article
Nicolson PL. et al, (2019), Clin Med (Lond), 19, 532 - 533
-
A HaemSTAR-led, UK-wide 'flash-mob' audit of -intravenous immunoglobulin use in immune -thrombocytopenia.
Journal article
Nicolson P. et al, (2019), Clin Med (Lond), 19, 82 - 83
-
Rebleeding and Mortality After Lower Gastrointestinal Bleeding in Patients Taking Antiplatelets or Anticoagulants.
Journal article
Oakland K. et al, (2019), Clin Gastroenterol Hepatol, 17, 1276 - 1284.e3
-
A HaemSTAR-led, UK-wide "Flash-Mob" audit of intravenous immunoglobulin use in immune thrombocytopenia
Conference paper
Nicolson PL. et al, (2019), BRITISH JOURNAL OF HAEMATOLOGY, 185, 9 - 10
-
Can long acting factors go a long way; a real-life single centre retrospective study of Haemophilia B patients who have switched to extended half-life factor IX
Conference paper
Rampotas A. et al, (2019), BRITISH JOURNAL OF HAEMATOLOGY, 185, 138 - 139
ORCID
0000-0002-1951-5616